Tuesday, October 15, 2013 No Region Specified
Source: Ariel Schwartz, Co.Exist
Pharmaceutical companies like to focus on developing two kinds of drugs: blockbuster drugs that lots of people use (like Lipitor), and more recently, extremely expensive niche drugs. Drugs targeted specifically for common afflictions that affect the developing world aren't as profitable and are often left out of the picture entirely. Global health nonprofit Path is trying to change that with an ambitious drug development program that targets diseases like kala-azar (also known as black fever disease), malaria, HIV, and diarrheal diseases, such as cholera.